Researchers Defend Elranatamab Cost-Effectiveness Model Against Methodological Criticisms in Multiple Myeloma
Authors of a multiple myeloma economic evaluation demonstrate that elranatamab maintains cost dominance over teclistamab across extensive sensitivity analyses despite ...


